MVI have a volume of resources to highlight how MVI and their partners are supporting not only the development of malaria vaccines, but their availability and use. We've made resources easy to navigate, grouped by type and presented to allow the user to approach them from any point of interest.
Looking to the next five years, the Malaria Vaccine Initiative will focus on two priority areas:
- Anti-infection vaccines (AIVs), which are meant to prevent infection in people bitten by infected mosquitoes.
- Transmission-blocking vaccines (TBVs), which aim to prevent mosquitoes from becoming infected with malaria parasites when they feed on infected people.
These two approaches target key points in the life cycle of the malaria parasite:
- when the parasite transitions between the mosquito and human host
- when parasite numbers are low.